ChromoGenics share and warrant TO1 start trading today on Nasdaq First North, Stockholm
ChromoGenics AB (publ) shares and warrants start trading today March 23 2017 on Nasdaq First North Stockholm. ChromoGenics is a leading provider of dynamic glass for solar control. The company focuses on window and facade glass for commercial buildings and addresses architects, real estate owners and construction companies.
In the recently completed rights issue (the "Offering"), a total of 13,800,000 shares and 13,921,312 TO1 were issued. The number of shares may be increased by a maximum of 121 312 for the event that it decided allotment option would be fully utilized. The price per "Unit" in the Offering consisting of one share and one TO1 amounted to SEK 8.50, corresponding to issue proceeds of SEK 117.3 million before issue costs.
After completion of the Offer, the number of outstanding shares in ChromoGenics is 23,214,326 shares, prior to exercise of the over-allotment option. Shares in the Offer thus comprises approximately 59.4 percent of the total shares of the Company and the market value of the Company's shares is approximately 197.3 MSEK.
The share's ticker name is CHRO, ISIN code: SE0009496268
The warrant’s ticker name is CHRO TO1, ISIN code: SE0009554470
Conditions for CHRO TO1 is that possession of four (4) TO1 entitles the holder to subscribe for one (1) new share in ChromoGenics at the rate of SEK 10.20 during the period 1 to 31 May 2018. The last trading day with TO1 is May 29, 2018.
The main shareholders K-Svets Venture AB and New Energy Solutions II K/S will after completion of the Offer remain as the major shareholders of ChromoGenics. K-Svets Venture AB will hold approximately 22 percent and New Energy Solutions II K/S around 19 percent of the shares in the company. Within the framework of the Offer, the main owners converted the bridge loan of approximately 23.2 MSEK corresponding to 2,725,443 Units
G&W Fondkommission is the financial advisor to ChromoGenics in connection with the transaction and appointed as Certified Adviser for the planned listing on Nasdaq First North Stockholm.
This information is such that ChromoGenics AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and according to the Act (1991: 980) regarding trading with financial instruments. The information was submitted for publication, through the agency of the contact person set out below, at 08:30 CET on March 23, 2017.
Every care has been taken in the translation of this interim report. In the event of discrepancies, the Swedish original will supersede the English translation.
Thomas Almesjö, CEO
Susanne Andersson, CFO & Head of Communications
Tel: +46 18 430 0430
ChromoGenics is a leader in dynamic glass with controllable heat- and light transmission. The company’s unique electrochromic technology ConverLight™, provides sustainable solar control with increased indoor comfort and energy efficiency. In 2016 the company started commercial sales to real estate projects in Scandinavia.
ChromoGenics is located in Uppsala and has about 20 employees. The technology is derived from the world leading research center at Ångström Laboratory at Uppsala University. The plant has been partly financed by a conditional loan from the Swedish Energy Agency. ChromoGenics share (CHRO) will be listed on Nasdaq First North Stockholm from March 23rd 2017. G&W Fondkommission is appointed Certified Adviser. www.chromogenics.com
In connection with the Offering, Erik Penser can implement measures that stabilize or maintain the share price. The warrants will not in any case be subject to any stabilization measures. These stabilization measures will not be implemented at higher prices than the offer price, 8.50 SEK. Such stabilization is intended to support the market price of the shares in order to balance any sales pressure that may be present and may be implemented in a period from the first day of trading in the Company's shares on Nasdaq First North to the date that falls 30 calendar days thereafter. Stabilization Measures include transactions that stabilize, maintain or otherwise affect the market price of the shares. Stabilization transactions consist of certain bids or purchases made for the purpose of preventing or retarding a decline in the shares' market price. Erik Penser is not obliged to take stabilization measures. Thus, there is no guarantee that the stabilization measures will be taken. If stabilization measures, the measures can at any time be terminated by Erik Penser Bank decision without notice. Erik Penser Bank's acquisition of shares in connection with the stabilization measures, at Erik Penser Bank's request neutralized by a reduced allotment. Stabilization Measures should not mean that Erik Penser in total acquire more than 121,312 shares. Neutralization by reducing the allotment may result in the number of warrants issued can not exceed the number of shares issued under the Offer up to 121,312. Within one week after the end of the period during which stabilization measures can be taken, it will be published by Erik Penser whether stabilization measures were carried out or not, the date on which stabilization started, the date of the last stabilization operation was performed and the price range within which stabilization was carried out (for each of the dates during which stabilization measures were carried out).